Peter DeMuth
Chief Tech/Sci/R&D Officer bij ELICIO THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Peter DeMuth is currently the Chief Scientific Officer at Elicio Therapeutics, Inc. He started this position in 2022.
He holds a doctorate degree from the Massachusetts Institute of Technology, which he received in 2013.
He also has an undergraduate degree from the University of Maryland, which he obtained in 2008.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 01-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Peter DeMuth
| Bedrijven | Functie | Begin |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2022 |
Eerdere bekende functies van Peter DeMuth
| Bedrijven | Functie | Einde |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-06-2023 |
Opleiding van Peter DeMuth
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
